Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.81)
# 92
Out of 5,124 analysts
26
Total ratings
77.27%
Success rate
36.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Assumes: Overweight | $9 | $2.43 | +270.37% | 1 | Nov 18, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $9.32 | +178.97% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $100.59 | +27.25% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $17.49 | +20.07% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $13.80 | +204.35% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $79.65 | -5.84% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $23.41 | +53.78% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $41.52 | +32.47% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $8.86 | +24.15% | 1 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $16.83 | +113.90% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.99 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.36 | +83.49% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $65.20 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $21.74 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.73 | - | 1 | Oct 31, 2022 |
Black Diamond Therapeutics
Nov 18, 2025
Assumes: Overweight
Price Target: $9
Current: $2.43
Upside: +270.37%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $9.32
Upside: +178.97%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $100.59
Upside: +27.25%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $17.49
Upside: +20.07%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $13.80
Upside: +204.35%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $79.65
Upside: -5.84%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $23.41
Upside: +53.78%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $41.52
Upside: +32.47%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $8.86
Upside: +24.15%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $16.83
Upside: +113.90%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.99
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $4.36
Upside: +83.49%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $65.20
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $21.74
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.73
Upside: -